Lyell Immunopharma Analyst Ratings
Lyell Immunopharma Analyst Ratings
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a downgraded with a price target of $15.00 to $5.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.29, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/28/2023 | 118.34% | JP Morgan | $15 → $5 | Downgrades | Overweight → Neutral |
| 05/05/2023 | 293.01% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 03/02/2023 | 293.01% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 01/24/2023 | 74.67% | Morgan Stanley | $7 → $4 | Maintains | Equal-Weight |
| 11/14/2022 | 205.68% | Morgan Stanley | $15 → $7 | Downgrades | Overweight → Equal-Weight |
| 11/11/2022 | — | Goldman Sachs | Downgrades | Buy → Neutral | |
| 10/17/2022 | 424.02% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 424.02% | Goldman Sachs | $21 → $12 | Maintains | Buy |
| 03/31/2022 | 817.03% | Goldman Sachs | $31 → $21 | Maintains | Buy |
| 01/06/2022 | 773.36% | Morgan Stanley | $25 → $20 | Maintains | Overweight |
| 07/12/2021 | 991.7% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 991.7% | B of A Securities | → $25 | Initiates Coverage On | → Buy |
| 07/12/2021 | 860.7% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 07/12/2021 | 1210.04% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月28日 | 118.34% | 摩根大通 | $15→$5 | 評級下調 | 超重→中性 |
| 05/05/2023 | 293.01% | HC Wainwright公司 | →$9 | 重申 | →購買 |
| 03/02/2023 | 293.01% | HC Wainwright公司 | $11→$9 | 維護 | 買 |
| 01/24/2023 | 74.67% | 摩根士丹利 | $7→$4 | 維護 | 等重 |
| 2022年11月14日 | 205.68% | 摩根士丹利 | $15→$7 | 評級下調 | 超重→等重 |
| 2022年11月11日 | - | 高盛 | 評級下調 | 購買→中性 | |
| 10/17/2022 | 424.02% | HC Wainwright公司 | →$12 | 開始承保 | →購買 |
| 2022年05月24日 | 424.02% | 高盛 | $21→$12 | 維護 | 買 |
| 03/31/2022 | 817.03% | 高盛 | $31→$21 | 維護 | 買 |
| 01/06/2022 | 773.36% | 摩根士丹利 | $25→$20 | 維護 | 超重 |
| 07/12/2021 | 991.7% | 摩根士丹利 | →$25 | 開始承保 | →超重 |
| 07/12/2021 | 991.7% | B of A證券 | →$25 | 開始承保 | →購買 |
| 07/12/2021 | 860.7% | 摩根大通 | →$22 | 開始承保 | →超重 |
| 07/12/2021 | 1210.04% | 高盛 | →$30 | 開始承保 | →購買 |
What is the target price for Lyell Immunopharma (LYEL)?
萊爾免疫療法(LYEL)的目標價格是多少？
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by JP Morgan on August 28, 2023. The analyst firm set a price target for $5.00 expecting LYEL to rise to within 12 months (a possible 118.34% upside). 7 analyst firms have reported ratings in the last year.
摩根大通於2023年8月28日報道了萊爾免疫飲(納斯達克：LYEL)的最新目標價。這家分析公司將LYEL的目標價設定為5美元，預計LYEL將在12個月內上漲(可能上漲118.34%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
萊爾免疫瘤(LYEL)的最新分析師評級是多少？
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by JP Morgan, and Lyell Immunopharma downgraded their neutral rating.
對萊爾免疫公司(納斯達克代碼：LYEL)的最新分析師評級由摩根大通提供，萊爾免疫公司下調了其中性評級。
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
萊爾免疫瘤(LYEL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公開的財務報表，與萊爾免疫公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。萊爾免疫瘤的上一次評級是在2023年8月28日提交的，所以你應該預計下一次評級將在2024年8月28日左右的某個時候公佈。
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
分析師對萊爾免疫毒瘤(LYEL)的評級正確嗎？
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a downgraded with a price target of $15.00 to $5.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.29, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的萊爾免疫公司(LYEL)評級被下調，目標價為15.00美元至5.00美元。萊爾免疫公司(LYEL)目前的交易價格為2.29美元，超出了分析師的預測區間。
